$132.68
-0.01 (-0.01%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
+73.71%
1Y
+208.63%
YTD
+75.09%
Open$132.78
Previous Close$132.69
Day High$132.89
Day Low$132.61
52W High$95.32
52W Low$34.34
Volume—
Avg Volume1.11M
Market Cap6.81B
P/E Ratio—
EPS$-4.33
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$73.88
Above
SMA 200
$52.13
Above
RSI (14)
48.1
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
25 analysts
Price Target
-23.4% upside
Current
$132.68
$132.68
Target
$101.57
$101.57
$78.76
$101.57 avg
$153.22
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 911.35M | 871.62M | 948.06M |
| Net Income | -243,438,723 | -174,175,180 | -203,637,440 |
| Profit Margin | -26.7% | -20.0% | -21.5% |
| EBITDA | -267,934,128 | -228,786,100 | -261,593,713 |
| Free Cash Flow | -101,879,133 | -97,401,406 | -128,866,616 |
| Rev Growth | +22.2% | +5.3% | +12.3% |
| Debt/Equity | 0.88 | 0.85 | 0.60 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $243.73 | +3.76% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $356.32 | +1.39% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $124.43 | -0.58% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $484.49 | +1.96% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $625.11 | +0.27% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $291.90 | -0.73% | 64.3 | 37.13B |